Korean J Obstet Gynecol.  2012 Nov;55(11):865-869. 10.5468/KJOG.2012.55.11.865.

Malignant peritoneal mesothelioma with nonspecific history: a case report

• Park JW
• Chu YC
• Hwang SO

• KMID: 2274158
• DOI: http://doi.org/10.5468/KJOG.2012.55.11.865

Abstract

Mesotheliomas are rare neoplasms of the pleura, peritoneum or pericardium, which are frequently associated with exposure to asbestos. Early diagnosis and establishment of a standard treatment for malignant peritoneal mesothelioma is difficult. We report on a case of malignant peritoneal mesothelioma in a 53-year-old woman with no history of exposure to asbestos or previous radiotherapy.

Keyword

Malignant mesothelioma; Peritoneum; Chemotherapy

MeSH Terms

Asbestos
Early Diagnosis
Female
Humans
Mesothelioma
Middle Aged
Pericardium
Peritoneum
Pleura
Asbestos

Figure

• 

  Fig. 1 Abdomino-pelvic computed tomography revealed 7.5 × 5.2 × 9.5 cm-sized lobulated contoured heterogeneously enhancing mass in right subhepatic space, multiple small nodular lesions with fatty infiltration in mesentery and omentum.

• 

  Fig. 2 (A,B) Positron emission tomography-computed tomography showed diffuse increased metabolic activity in peritoneum and mesentery of right subhepatic space.

• 

  Fig. 3 (A) The tumor revealed solid sheet-like arrangement of malignant epithelial mesothelial cells and short fascicles of spindle shaped malignant mesothelial cells. Epithelial mesothelial cells showed vesicular nuclei, macronucleoli, and abundant glassy eosinophilic cytoplasm resembling a decidual reaction (H&E, ×100). (B) Frequent mitotic figures and necrosis are also found (H&E, ×200).

• 

  Fig. 4 Immunohistochemistry showed calretinin positive tumor cells (immunohistochemical stain, ×100).

Reference

1. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009. 27:2081–2090.

2. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992. 34:718–721.

3. Teta MJ, Lau E, Sceurman BK, Wagner ME. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer. 2007. 109:1432–1438.

4. De Bruin ML, Burgers JA, Baas P, van't Veer MB, Noordijk EM, Louwman MW, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood. 2009. 113:3679–3681.

5. Plaus WJ. Peritoneal mesothelioma. Arch Surg. 1988. 123:763–766.

6. Asensio JA, Goldblatt P, Thomford NR. Primary malignant peritoneal mesothelioma. A report of seven cases and a review of the literature. Arch Surg. 1990. 125:1477–1481.

7. Larson T, Melnikova N, Davis SI, Jamison P. Incidence and descriptive epidemiology of mesothelioma in the United States, 1999-2002. Int J Occup Environ Health. 2007. 13:398–403.

8. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999. 79:666–672.

9. McCaughey WT, Kannerstein M, Churg J. Armed Forces Institute of Pathology (US). Universities Associated for Research and Education in Pathology. Tumors and pseudotumors as the serous membranes. 1985. Washington, DC: Armed Forces Institutes of Pathology.

10. Soltermann A, Pache JC, Vogt P. Metastasis of a pleural mesothelioma to a hyperplastic stomach polyp: an increase of vimentin expression is seen during a gain in deciduoid morphology. Rare Tumors. 2011. 3:e52.

11. Truong LD, Maccato ML, Awalt H, Cagle PT, Schwartz MR, Kaplan AL. Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases. Hum Pathol. 1990. 21:99–110.

12. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008. 132:397–401.

13. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008. 9:147–157.

14. Turner K, Varghese S, Alexander HR Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw. 2012. 10:49–57.

15. Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, et al. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol. 2012. 106:197–203.